Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

62462 1502285060HCLSReviewMexicoJuly2017.pdf
Energy Boardroom

Celgene beats on earnings, despite decline in U.S. Revlimid sales

24.04.2014 / Fierce Pharma

Celgene's earnings topped expectations for the first quarter, as its blood-cancer drug Revlimid continued to deliver double-digit sales growth.

LATEST ISSUE

DOWNLOAD

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: